This paper is only available as a PDF. To read, Please Download here.
Abstract
In the present study we measured fasting lipid profiles in over 8,500 community-living
men with coronary artery disease (CAD) to determine the distribution of lipid abnormalities
in this population: 81% were white and 16% black; mean age 62.9 ± 8 years; mean total
cholesterol 214 ± 41 mg/dl; low-density lipoprotein (LDL) cholesterol 140 ± 37 mg/dl;
high-density lipoprotein (HDL) cholesterol 39 ± 11 mg/dl; and triglycerides 190 ±
142 mg/dl. After adjusting for age, the only significant difference between blacks
and whites was a higher HDL cholesterol in blacks (45 vs 38 mg/dl, p < 0.003). With
use of cut points established by the National Cholesterol Education Program, 87% or
subjects had high LDL cholesterol (≥100 mg/dl), 38% had low HDL cholesterol (<35 mg/dl),
and 33% had high triglycerides (>200 mg/dl). We estimated that 42% of men with CAD
would be definite candidates for cholesterol-lowering medication according to the
National Cholesterol Education Program guidelines and that 41% of those in whom cholesterol-lowering
medication would not be definitely indicated had low levels of HDL cholesterol. We
conclude that (1) black men with CAD have substantially higher HDL cholesterol than
white men, (2) almost 90% of male patients with CAD are candidates for dietary intervention
and >40% may need medications to lower LDL cholesterol, and (3) 40% of patients without
a definite indication for cholesterol-lowering medications have low levels of HDL
cholesterol.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).in: 6th ed. publication no. 93-3095. National Institutes of Health, Bethesda, MD1993
- Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study.Ann Intern Med. 1991; 115: 687-693
- Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.N Engl J Med. 1990; 322: 1700-1707
- Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study.Am Heart J. 1987; 113: 1356-1364
- Prognostic importance of cholesterol levels after myocardial infarction.Prev Med. 1984; 13: 355-366
- Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease.Am J Cardiol. 1990; 65: 1-5
- Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels.Am J Cardiol. 1991; 68: 187-192
- Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.Am J Cardiol. 1993; 71: 45-52
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge.Clin Chem. 1972; 18: 499-508
- 6th ed. SAS/STAT Statistical User's Guide. SAS Institute Inc.,, Cary, NC1993
- Dietary reduction of serum cholesterol concentration: time to think again.Br Med J. 1991; 303: 953-957
- Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women.Circulation. 1992; 86: 839-848
- Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study.Circulation. 1979; 60: 427-439
- Declining serum total cholesterol levels among US adults.JAMA. 1993; 269: 3002-3008
- Lipoprotein lipids in older people: results from the Cardiovascular Health Study.Circulation. 1992; 86: 858-869
- Plasma high-density lipoprotein cholesterol comparisons in black and white populations: the Lipid Research Clinics Program Prevalence Study.Circulation. 1980; 62: IV-99-IV-107
- Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study.Arterioscler Thromb. 1993; 13: 1139-1158
- Prevalence of risk factors in men with premature coronary artery disease.Am J Cardiol. 1991; 67: 1185-1189
- Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease.Am J Cardiol. 1991; 67: 479-483
- A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.N Engl J Med. 1991; 325: 373-381
- Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction.Circulation. 1992; 85: 22-29
- High density lipoprotein cholesterol and triglycerides as markers of angiographically assessed coronary artery disease.Br Med J. 1990; 63: 78-81
- The Dubbo Study of the health of elderly: correlates of coronary heart disease at study entry.J Am Geriatr Soc. 1991; 39: 584-590
- Prevalence of high blood cholesterol among US adults.JAMA. 1993; 269: 3009-3014
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE).Am J Cardiol. 1991; 68: 1436-1446
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).Am J Cardiol. 1993; 71: 909-915
- Prognostic implications of serum cholesterol in coronary heart disease.in: Jones RJ Atherosclerosis: Proceedings of the Second International Symposium. Springer-Verlag, New York1970: 393-405
- National Cholesterol Education Program's recommendations and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programs.Am J Cardiol. 1991; 68: 1087-1088
- Distribution of lipid phenotypes in community-living men with coronary heart disease: high prevalence of isolated low levels of high-density lipoprotein cholesterol.Arch Intern Med. 1992; 152: 2412-2416
Article Info
Publication History
Accepted:
April 4,
1995
Received:
February 8,
1995
Identification
Copyright
© 1995 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.
User License
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
